Source: Healio Coverage
October 09, 2020
1 min read
Save

Top in GI: Small intestine bacterial overgrowth breath test, alternative IBS therapies

Source: Healio Coverage
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Cedars-Sinai recently launched a breath test to help diagnose small intestine bacterial overgrowth related to irritable bowel syndrome. It was the top story in gastroenterology last week.

Another top story was about a study that showed certain alternative therapies may be beneficial for patients with irritable bowel syndrome (IBS).

Read these and more top stories in gastroenterology below:

Q&A: New breath test adds hydrogen sulfide to better understand the microbiome in patients

Healio spoke with Mark Pimentel, MD, executive director of the medically associated science and technology program at Cedars-Sinai, about the small intestine bacterial overgrowth breath test and what this new device means for patient care. Read more.

Some alternative therapies may be beneficial in IBS

Some complimentary alternative therapies, including herbal and dietary supplements, may help ease abdominal pain and benefit overall response in patients with IBS, according to study results. Read more.

VIDEO: GIs ‘can play a crucial role’ in post-pandemic vaccinations

In this video, Freddy Caldera, DO, MS, from the division of gastroenterology and hepatology at the University of Wisconsin School of Medicine and Public Health, discusses his paper on reducing the risk for vaccine-preventable disease during the COVID-19 pandemic. Read more.

Patient-favored discontinuation improved with Entyvio, Stelara in IBD

Patient preference favoring treatment discontinuation was improved during treatment with Entyvio (vedolizumab, Takeda) or Stelara (Ustekinumab, Janssen) compared with anti-TNF therapy in patients with inflammatory bowel disease, according to study results. Read more.

Real-world data from AGA registry shows FMT highly effective for CDI

A prospective real-world study showed fecal microbiota transplantation was highly effective for Clostridioides difficile infection and had a good safety profile, according to new data published in Gastroenterology. Read more.